Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 1, 2010, Pages 43-54

  Highlander, Peter ^a   Shaw, Graham P ^a  

^a BARRY UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Endothelial cell

Indexed keywords

ANTIHYPERTENSIVE AGENT; ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFONIDIPINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LABETALOL; LOSARTAN; METOPROLOL; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PLACEBO; PROPRANOLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ANIMAL; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; CELL FUNCTION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG CLASSIFICATION; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; TISSUE REPAIR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; OBESITY;

EID: 77949909104     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709354305     Document Type: Review

References (112)

1. Adler, A.I., Stevens, R.J., Neil, A., Stratton, I.M., Boultone, A.J. and Holman, R.R. ( 2002) UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25: 894-899.
2. Aksnes, T.A., Schmieder, R.E., Kjeldsen, S.E., Ghani, S., Hua, T.A. and Julius, S. ( 2008) Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 101: 634-638.
3. Anderson, T.J., Elstein, E., Haber, H. and Charbonneau, F. ( 2000) Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 35: 60-66.
4. Andersen, K., Weinberger, M.H., Egan, B., Constance, B., Ali, M.A., Jin, J. et al. (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension; a 6-month, randomized, double blind trial. J Hypertens 26: 589-599.
5. Ansell, B.J., Watson, K.E., Weiss, R.E. and Fonarow, G.C. ( 2003) hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis 5: 2-7.
6. Avogaro, A., Miola, M., Favaro, A., Gottardo, L., Pacini, G. et al. (2001) Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 31 (7): 603-609.
7. Bartnik, M., Malmberg, K., Hamsten, A., Efendic, S., Norhammar, A., Silverira, A. et al. (2004) Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Int Med 256: 288-297.
8. Bakris, G.L. ( 2007) Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Managed Care Pharmacy (Suppl) 13: S9-S12.
9. Bakris, G.L., Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Phillips, R.A. et al. GEMINI Investigators (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension a randomized controlled trial. JAMA 292: 2227-2236.
10. Bell, D.H. ( 2003) Use of beta blockers in the patient with diabetes. Endocrinologist 13: 116-123.
11. Bell, D.S. ( 2004) Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 93: 49B-52B.
12. Berkels, R., Tabert, D., Bartels, H., Breitenbach, T., Klas, W. and Roesen, R. ( 2004) Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 70: 39-45.
13. Black, J.W. and Stephenson, J.S. ( 1962) Pharmacology of a new adrenergic beta-receptor blocking compound. Lancet 2: 311-314.
14. Bramlage, P., Durand-Zaleski, I., Desai, N., Pirk, O. and Hacker, C. (2009) The value of irbesartan in the management of hypertension. Expert Opinion Pharmacother 10: 1817-1831.
15. Celik, T., Iyisoy, A., Kursaklioglu, H., Kardesoglu, E., Kilic, S., Turhan, H. et al. (2006) Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24: 591-596.
16. Cheetham, C., O'Driscoll, G., Stanton, K., Taylor, R. and Green, D. ( 2001) Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (Lond) 100: 13-17.
17. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, Jr J.L. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. Hypertension 42: 1206-1252.
18. Chrysant, S.G. and Chrysant, G.S. ( 2006) The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich) 8: 261-268.
19. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J. et al. CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
20. Collins, R., Armitage, J., Parish, S., Sleigh, P. and Peto, R. Heart Protection Study Collaborative Group ( 2003) MRC / BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 14: 2005-2016.
21. Cooper-De Hoff, R.M. ( 2008) Thiazide-induced dysglycemia: it's time to take notice. Expert Rev Cardiovasc Ther 6: 1291-1294.
22. Dalla Nora, E., Passaro, A., Zamboni, P.F., Calzoni, F. and Solini, A. ( 2003) Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 26: 73-78.
23. Darko, D., Dornhorst, A., Kelly, F.J., Ritter, J.M. and Chowienczyk, P.J. ( 2002) Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clin Sci (Lond) 103: 339-344.
24. de Cobelli, F., Fiorina, P., Perseghin, G., Magnone, M., Venturini, M., Zerbini, G. et al. (2004) L-arginine-induced vasodilation of the renal vasculature is preserved in uremic type 1 diabetic patients after kidney and pancreas but not after kidney-alone transplantation. Diabetes Care 27: 947-954.
25. DECODE study group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621.
26. Doshi, K.B., Kashyap, S.R., Brennan, D.M., Hoar, B.M., Cho, L. and Hoogwerf, B.J. (2009) All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study. Diabetes Obes Metab 11: 102-108.
27. Dumont, A.S., Hyndman, M.E., Dumont, R.J., Fedak, P.M., Kassell, N.F., Sutherland, G.R. et al. (2001) Improvement of endothelial function in insulin-resistant carotid arteries treated with pravastatin. J Neurosurg 95: 466-471.
28. Eckel, R.H., Wassef, M., Chait, A., Sobel, B., Barrett, E., King, G. et al. (2002) Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 105: e138-e143.
29. Fegan, P.G., Shore, A.C., Mawson, D., Tooke, J.E. and MacLeod, K.M. ( 2005) Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 22: 1670-1676.
30. Food and Drug Administration (2007) FDA approves new drug treatment for high blood pressure. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108862.htm.
31. Fonseca, V., Bakris, G.L., Bell, D.S., McGill, J.B., Raskin, P., Messerli, F.H. et al. for the GEMINI Investigators ( 2007) Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabetes Med 24: 759-763.
32. Fossum, E., Gleim, G.W., Kjeldsen, S.E., Kizer, J.R., Julius, S., Devereux, R.B. et al. (2007) The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. J Intern Med 262: 439-448.
33. Frampton, J.E. and Curran, M.P. ( 2007) Aliskiren. A review of its use in the management of hypertension. Drugs 67: 1767-1792.
34. Fuchsjäger-Mayrl, G., Pleiner, J., Wiesinger, G.F., Sieder, A.E., Quittan, M., Nuhr, M.J. et al. (2002) Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care 25: 1795-1801.
35. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V.H., Parving, H.-H. and Pedersen, O. ( 2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393.
36. Gaede, P., Lund-Andersen, H., Parving, H.H. and Pedersen, O. ( 2008) Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591.
37. Goldberg, I.J. ( 2001) Diabetic dyslipidemia causes and consequences. J Clin Endocrinol Metab 86: 965-971.
38. Griffin, S.J., Echouffo-Tcheugui, J.B., Sargeant, L.A., Prevost, A.T., Williams, K.M., Barling, R.S. et al. (2008) How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabetic Medicine 25: 1433-1439.
39. Gudbjörnsdottir, S., Eeg-Olofsson, K., Cederholm, J., Zethelius, B., Eliasson, B. and Nilsson, P.M. (2009) Risk factor control in patients with type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabetic Medicine 26: 53-60.
40. Hadi, H.A.R. and Al Suwaidi, J. ( 2007) Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management 3 (6): 853-876.
41. Hayashi, Y., Okumura, K., Matsui, H., Imamura, A., Miura, M., Takahashi, R. et al. (2007) Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 56: 608-613.
42. Helijić, B., Velija-Asimi, Z. and Kulić, M. (2009) The statins in prevention of coronary heart disease in type 2 diabetics. Bosn J Basic Med Sci 9: 71-76.
43. Hermann, T.S., Li, W., Domiguez, H., Ihlemann, N., Rask-Madsen, C., Major-Pedersen, A. et al. (2006) Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 1001-1008.
44. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M. et al. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22.
45. Hornig, B., Landmesser, U., Kohler, C., Ahlersmann, D., Spiekermann, S., Christoph, A. et al. (2001) Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103: 799-805.
46. Ingelfinger, J.R. ( 2008) Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 358: 2503-2505.
47. Jenkins, N.P., Keevil, B.G., Hutchinson, I.V. and Brooks, N.H. ( 2002) Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 112: 269-274.
48. Kabat, A. and Dhein, S. ( 2006) L-arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia. Pharmacology 76: 185-191.
49. Kalus, J.S., Coleman, C.I. and White, C.M. ( 2006) The impact of suppressing the rennin-angiotensin system on atrial fibrillation. J Clin Pharmacol 46: 21-28.
50. Kazama, H., Usui, S., Okazaki, M., Hosoi, T., Ito, H. and Orimo, H. ( 2003) Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 59: 181-189.
51. Keating, G.M. and Croom, K.F. ( 2007) Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67: 121-53.
52. Knopp, R.H., D'Emden, M., Smilde, J.G. and Pocock, S.J. ( 2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atrovastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes mellitus (ASPEN). Diabetes Care 29: 1478-1485.
53. Koba, S., Yokota, Y., Hirano, T., Ito, Y., Ban, Y., Tsunoda, F. et al. (2008) Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 15: 250-260.
54. Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H. et al. (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110: 3687-3692.
55. Koh, K.K., Quon, M.J., Han, S.H., Ahn, J.Y., Jin, D.K., Kim, H.S. et al. (2005) Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes mellitus. Hypertension 45: 1088-1093.
56. Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Kim, J.A. et al. (2006) Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic, hypertensive patients. Diabetes Care 29: 195-201.
57. Kowalska, I., Prokop, J., Bachorzewska-Gajewska, H., Telejko, B., Kinalskal, I., Kochman, W. et al. (2001) Disturbances of glucose metabolism in men referred for coronary arteriography. Post load glycemia as a predictor for coronary atherosclerosis. Diabetes Care 24: 897-901.
58. Krentz, A.J. ( 2003) Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 5(Suppl. 1): S19-S27.
59. Kvan, E., Pettersen, K.I., Sandvik, L. and Reikvam, A. ( 2007) High mortality in diabetic patient with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk. Int J Cardiol 121: 184-188.
60. Lau, D.C.W. (2009) Metabolic syndrome: Perception or reality? Curr Atheroscler Rep 11: 264-271.
61. Lewis, P.J., Kohner, E.M., Petrie, A. and Dollery, C.T. ( 1976) Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 13: 564-566.
62. Liebson, P.R. and Amsterdam, E.A. (2009) Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol 12: 43-50.
63. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
64. McFarlane, S.I., Kumar, A. and Sowers, J.R. ( 2003) Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91: 30H-37H.
65. McSorly, P.T., Bell, P.M., Young, I.S., Atkinson, A.B., Sheridan, B., Fee, J.P. et al. (2005) Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial. Diabet Med 22: 703-710.
66. McVeigh, G.E. and Cohn, J.N. ( 2003) Endothelial dysfunction and the metabolic syndrome. Curr Diab Rep 3: 87-92.
67. Meier, J.J., Deiflus, S., Gallwitz, B., Klamann, A., Schmiegel, W. and Nauck, M.A. ( 2002) Influence of impaired glucose tolerance on long term survival after acute myocardial infarction. The Langerdree Myocardial infarction and blood glucose in Diabetic patients Assessment (LAMBDA). Dtsch Med Wochenschr 127: 1123-1129.
68. Messerli, F.H., Williams, B. and Ritz, E. ( 2007) Essential hypertension. Lancet 370: 591-603.
69. Morgan, J.M., Carey, C.M., Lincoff, A. and Capuzzi, D.M. ( 2004) The effects of niacin on lipoprotein subclass distribution. Prev Cardiol 7: 182-187.
70. Movahed, M.R., Hashemzadeh, M. and Jamal, M. ( 2007) Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels 22: 251-253.
71. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y. et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
72. Norhammar, A., Malmberg, K., Diderhol, E., Lagerqvist, B., Lindahl, B., Rydén, L. et al. (2004) Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43: 585-591.
73. Omori, H., Nagashima, H., Tsurumi, Y., Ishizuka, N., Hagiwara, N. et al. (2002) Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in health normocholesterolaemic subjects. Br J Clin Pharmacol 54 (4): 395-399.
74. ONTARGET investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
75. Oparil, S., Yarows, S.A., Patel, S., Fang, H., Zhang, J. and Satlin, A. ( 2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 370: 221-229.
76. Oshima, T., Ozono, R., Yano, Y., Higashi, Y., Teragawa, H., Miho, N. et al. (2005) Beneficial effects of T-type calcium channel blockers on endothelial cell function in patients with essential hypertension. Hypertens Res 28: 889-894.
77. Otsuki, M., Goya, K. and Kasayama, S. ( 2005) Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vascular Health and Risk Management 1: 209-215.
78. Patel, A., ADVANCE Collaborative Group, MacMahon, S., Chalmers, J., Neal, B., Woodward, M. et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 370: 829-840.
79. Petrie, J.R., Morris, A.D., Minamisawa, K., Hilditch, T.E., Elliott, H.L., Small, M. et al. (1998) Dietary sodium restriction impairs insulin sensitivity in non insulin-dependent diabetes mellitus. J Endocrinol Metab 83: 1552-1557.
80. Pradhan, A.D., Manson, J.E., Rifai, N., Buing, J.E. and Ridker, P.M. ( 2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334.
81. Prasad, A., Tupas-Habib, T., Schenke, W.H., Mincemoyer, R., Panza, J.A., Waclawin, M.A. et al. (2000) Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 101: 2349-2354.
82. Regensteiner, J.G., Popylisen, S., Bauer, T.A., Lindenfeld, J., Gill, E., Smith, S. et al. (2003) Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 8: 169-175.
83. Rojas, A. and Morales, M.A. ( 2004) Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci 76: 715-730.
84. Rosenson, R.S., Abby, S.L. and Jones, M.R. (2009) Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 204: 342-344.
85. Sachidanandam, K., Hutchinson, J.R., Elgebaly, M.M., Mezzetti, E.M., Dorrance, A.M., Motamed, K. et al. (2009) Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol 296: R952-R959.
86. Sahach, V.F., Prysiazhna, O.D., Tkachenko, M.N. and Kotsiuruba, A.V. ( 2005) Effect of L-arginine on the endothelium functional activity in experimental diabetes mellitus. Fiziol Zh 51: 3-7.
87. Sato, N., Kase, H. and Kato, T. ( 2003) Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension. Nippon Rinsho 61: 1245-1249.
88. Schiffrin, E.L., Pu, Q. and Park, J.B. ( 2002) Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 15: 105-110.
89. Sever, P. ( 2006) New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 7: 61-63.
90. Shah, S., Kublaoui, B.M., Oden, J.D. and White, P.C. (2009) Screening for type 2 diabetes in obese youth. Pediatrics 124: 573-579.
91. Shammas, N.W., Sica, D.A. and Toth, P.P. (2009) A guide to the management of blood pressure in the diabetic hypertensive patient. Am J Cardiovasc Drugs 9: 149-162.
92. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W. et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307.
93. Siphai, I., Tuzcu, E.M., Wolski, K.E., Nicholls, S.J., Schoenhagen, P., Hu, B. et al. (2007) Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147: 10-18.
94. Sniderman, A.D., Scantlebury, T. and Cianflone, K. ( 2001) Hypertriglyceridemic hyper Apo B: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135: 447-459.
95. Stafford, R.S., Monti, V., Furberg, C.D. and Ma, J. ( 2006) Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 48: 213-218.
96. Stanton, A., Jensen, C., Nussberger, J. and O'Brien, E. ( 2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42: 1137-43.
97. Strippoli, G.F., Craig, M., Deeks, J.J., Schena, F.P. and Craig, J.C. ( 2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. BMJ 329: 828.
98. Tan, K.C., Chow, W.S., Tam, S.C., Ai, V.H., Lam, C.H. and Lam, K.S. ( 2002) Atrovastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Endocrinol Metab 87: 563-568.
99. Tekin, A., Tekin, G., Sezgin, A.T. and Muderrisoglu, H. ( 2008) Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. Pharmacological Research 57: 393-397.
100. Tsunekawa, T., Hayashi, T., Kano, H., Sumi, D., Matsui-Hirai, H., Thakur, N.K. et al. (2001) Cerivastatin a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104: 376-379.
101. Uresin, Y., Taylor, A.A., Kilo, C., Tschope, D., Santonastaso, M., Ibram, G. et al. (2007) Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone System 8: 190-198.
102. van de Ree, M.A., Huisman, M.V., de Man, F.H., van der Vijver, J.C., Meinders, A.E. and Blauw, G.J. ( 2001) Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simavastatin. Cardiovasc Res 52: 299-305.
103. van Venrooij, F.V., van de Ree, M.A., Bots, M.L., Stolk, R.P., Huisman, M.V. and Banga, J.D. DALI Study Group (2002) Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25: 1211-1216.
104. Verma, S., Buchman, M.R. and Anderson, T.J. ( 2003) Endothelial function testing as a biomarker of vascular disease. Circulation 108: 2054-2059.
105. Verma, S., Kuliszewski, M.A., Li, S.H., Szmitko, P.E., Zucco, L., Wang, C.H. et al. (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109: 2058-2067.
106. Waugh, N., Scotland, G., McNamee, P., Brennan, A., Govder, E. et al. (2007) Screening for type 2 diabetes: literature review and economic modeling. Health Technol Assess 11 (17): 1-125.
107. Weber, K., Bohmeke, T., van der Does, R. and Taylor, S.H. (1996) Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 10: 113-117.
108. Wood, J.M., Maibam, J. and Rahuel, J. ( 2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308: 698-705.
109. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. ( 2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
110. Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J. et al. (2004) Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 116: 460-465.
111. Zhang, Y., Dall, T.M., Mann, S.E., Chen, Y., Martin, J., Moore, V. et al. (2009) The economic costs of undiagnosed diabetes. Populat Health Manage 12: 95-101.
112. Zhou, M.S., Jaimes, E.A. and Raij, L. ( 2004) Inhibition of oxidative stress and improvement of endothelial function by amlodopine in angiotensin II-infused rats. Am J Hypertension 17: 167-171.